Peritoneal Cancer
📧 Sign up to get email alerts when something new happens for Peritoneal Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-05-23Clinical Trial Update: Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer [Phase 1, Phase 2]
Withdrawal notice for a Phase 1/Phase 2 trial of Niraparib with selenium in BRCA-negative, platinum-resistant fallopian tube, ovarian, and p…
-
CLINICAL_TRIALS trial_result · 2025-05-22Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis [Phase 1]
Phase 1 study evaluating nivolumab with or without ipilimumab in patients with recurrent or high-grade gynecologic cancers and metastatic pe…
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors [Phase 1]
A Phase 1 trial is evaluating the addition of Elimusertib, an ATR inhibitor, to gemcitabine for advanced pancreatic and ovarian cancers and …
-
CLINICAL_TRIALS trial_result · 2025-05-22Clinical Trial Update: Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients [NA]
A completed clinical trial evaluated post-operative intravenous ketorolac for GTPase inhibition in ovarian cancer patients. The study also i…
-
CLINICAL_TRIALS research · 2025-05-21Clinical Trial Update: MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors [Phase 1]
MT027 is being studied in a Phase 1 trial for patients with B7-H3-positive advanced malignant solid tumors, including primary peritoneal can…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) [NA]
A clinical trial named PRESERVE is evaluating perioperative stress reduction versus standard of care in patients with ovarian cancer and rel…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer [Phase 2, Phase 3]
Results from a Phase 2/3 trial evaluating the combination of cediranib and olaparib versus each drug alone or chemotherapy in recurrent plat…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer [Phase 2, Phase 3]
Phase 2/3 trial updating the combination of cediranib and olaparib versus each drug alone or other chemotherapy in recurrent platinum-resist…
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
This clinical trial update describes a Stanford-sponsored study investigating BRCA1/BRCA2-associated tumors and the collection of related tu…
-
CLINICAL_TRIALS trial_result · 2025-04-30Clinical Trial Update: Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial of relacorilant with nab-paclitaxel in recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer has …
-
CLINICAL_TRIALS trial_result · 2025-04-23Clinical Trial Update: Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer
This update notes the completion of a clinical trial evaluating geriatric assessment plus nursing telephone support for elderly women with o…
-
CLINICAL_TRIALS research · 2025-04-16Clinical Trial Update: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer [Phase 3]
This update notes a Phase 3 trial evaluating relacorilant in combination with nab-paclitaxel for advanced platinum-resistant ovarian, primar…
-
CLINICAL_TRIALS trial_result · 2025-04-13Clinical Trial Update: Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 3]
Phase 3 study comparing IBI354 to investigator's choice chemotherapy in platinum-resistant ovarian, primary peritoneal, or fallopian tube ca…
-
CLINICAL_TRIALS withdrawal · 2025-04-06Clinical Trial Update: Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi [Phase 2]
A Phase 2 trial evaluating dostarlimab plus niraparib for relapsed ovarian, fallopian tube, or primary peritoneal cancer has been withdrawn.…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer [Phase 2]
A Phase 2 clinical trial update for Mirvetuximab soravtansine (IMGN853) in FRα-high recurrent ovarian, fallopian tube, or primary peritoneal…
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]
Phase 1 trial update of MOv19-BBz CAR T cells targeting aFR-expressing recurrent high-grade serous ovarian, fallopian tube, or primary perit…
-
CLINICAL_TRIALS withdrawal · 2025-03-19Clinical Trial Update: A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer's post-marketing surveillance study of Zirabev to assess safety and effectiveness in domestic cancer patients has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-03-13Clinical Trial Update: Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update of atezolizumab, guadecitabine, and CDX-1401 vaccine in recurrent platinum-resistant ovarian, fallopian tube, and prim…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: BP1001-A in Patients With Advanced or Recurrent Solid Tumors [Phase 1]
This clinical trial update states that BP1001-A is being evaluated in a Phase 1 study for advanced or recurrent solid tumors and is currentl…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2, Phase 3]
This clinical trial update reports results from a Phase 2/3 study evaluating pegylated liposomal doxorubicin in combination with atezolizuma…
-
CLINICAL_TRIALS trial_result · 2025-02-21Clinical Trial Update: Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer [Phase 1]
Phase 1 study evaluating intraperitoneal carboplatin with intravenous paclitaxel and bevacizumab in untreated ovarian cancer has completed.
-
CLINICAL_TRIALS research · 2025-02-21Clinical Trial Update: Genetic Testing in African Americans [NA]
Clinical trial update on genetic testing in African American participants related to ovarian cancer, endometrial cancer, and peritoneal canc…
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients [EARLY_Phase 1]
Early-phase 1 clinical trial evaluating heated intraperitoneal chemotherapy with doxorubicin and cisplatin for pediatric abdominal/pelvic tu…
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: PARPi and Ovarian Cancer Survival
A not-yet-recruiting clinical trial is investigating a PARP inhibitor for epithelial ovarian cancer and related cancers of the fallopian tub…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1]
A Phase 1 trial evaluates the combination of mirvetuximab soravtansine and rucaparib camsylate in patients with recurrent gynecologic cancer…